Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Key points 1. This is one of the very few prospective trials focusing on refractory multiple myeloma with extramdedullary disease (EMD). 2. We successfully laid grounds for implementing immunochemotherapy in EMD treatment.
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2022-10-01
|
| Col·lecció: | Journal of Hematology & Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s13045-022-01374-5 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|